Status:
NOT_YET_RECRUITING
Tryptophan as a Modulating Factor in the Antimigraine Efficacy of Triptans
Lead Sponsor:
University Hospital, Clermont-Ferrand
Collaborating Sponsors:
University of the Basque Country (UPV/EHU)
Lariboisière Hospital
Conditions:
Migraine
Eligibility:
All Genders
18-50 years
Brief Summary
Migraine is a leading cause of disability, and while triptans are commonly used to treat migraine attacks, over 20% of patients don't respond well to them. This study aims to understand why some peopl...
Detailed Description
Migraine is a leading cause of disability worldwide. Triptans are medications used to treat migraine attacks. They work mainly in two ways: by narrowing the blood vessels in the brain and by stopping ...
Eligibility Criteria
Inclusion
- Cisgender women, premenopausal, aged 18 to 50 years.
- Cisgender men, aged 18 to 50 years.
- Diagnosed with migraine (according to ICHD-3 criteria).
- Diagnosed as responders or non-responders to triptans (according to the criteria of Sacco et al., 2022).
- Permitted comparison groups include: triptans used alone or in combination with other migraine treatments (e.g., NSAIDs, acetaminophen, ergotamine, opioids, antiemetics).
- All routes of administration and all dosages.
- Affiliation with a social security system.
Exclusion
- Patients under guardianship, curatorship, deprivation of liberty, or legal protection
- Pregnant and breastfeeding women
Key Trial Info
Start Date :
November 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2028
Estimated Enrollment :
144 Patients enrolled
Trial Details
Trial ID
NCT07177885
Start Date
November 1 2025
End Date
November 1 2028
Last Update
September 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Clermont-Ferrand
Clermont-Ferrand, France